Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma

Bendamustine is an increasingly used hybrid alkylating agent that is active in lymphoid neoplasias via a novel mechanism of action. There are some pending questions about its use in clinical practice because of its developmental features. A consensus panel of several leading Spanish hematologists with broad experience in the clinical use of bendamustine has established recommendations for the management and treatment of hematological patients with bendamustine based on available clinical data and the experience of the participants. These recommendations address the dose and treatment regimen for different clinical indications, the management of toxicity, and support therapy. This article contains the conclusions of this consensus panel, which are intended to serve as guidelines for the use of bendamustine.

[Burkitt's lymphoma. Report of six cases (author's transl)]

Authors report six cases on Burkitt's lymphoma seen during the last 18 months. In all of them a large ileocecal tumor was present and five of them had a bone marrow involvement. The ascitic fluid was positive in all cases. Three of the patients had a marked jaundice at diagnosis. The immunologic markers study on two of the cases, made evident that they belonged to type B. One of these two cases showed a component M in serum of the IgM type. As soon as chemotherapy started two of the cases showed marked metabolic disturbances. Three of the cases died and the three others remain free of disease for as long as two, 26 and 21 months. This report arises a comment epidemiologic importance of the increased frequency of Burkitt's lymphoma during the last months, as well as the clinic features of the six reported cases as compared to series published in non endemic areas on this topic.